https://www.zh.ch/de/volkswirtschaftsdirektion/amt-fuer-wirtschaft/standortfoerderung.html  

8090 Zürich, Walchestrasse 19

 +41 43 259 49 92
 standort@vd.zh.ch

The Division of Business and Economic Development supports resident companies, promotes Zurich's innovation capacity by way of connecting the relevant stakeholders in key industries, fosters external economic relations and offers guidance to companies interested in moving to Zurich.

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18

 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

https://www.schlieren.ch/standortfoerderung  

8952 Schlieren, Freiestrasse 6

  +41 44 738 14 11
 stadtbuero@schlieren.ch

Location Promotion strengthens the dialog between politics, administration and business and maintains a large network of contacts. It implements the city's economic strategy, promotes young entrepreneurship, provides advice on company relocations and arranges office and commercial space. It also strengthens Schlieren as a business location by devising individual development strategies for underutilized sites.

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

http://www.molecularpartners.com  

8952 Schlieren, Wagistrasse 14

 +41 44 755 77 00

Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

http://www.dualsystems.com  

8952 Schlieren, Grabenstrasse 11a

 +41 44 738 50 00
 info@dualsystems.com

Dualsystems Biotech is a provider of proteomics services for industry and academia.

https://www.rqmicro.com  

8952 Schlieren, Brandstrasse 24

 +41 44 512 51 51

rqmicro’s separation and detection technology for microbiological tests in the water and food industry delivers reliable, quantitative and cost-effective results in less than 2 hours.

http://www.topadur.com/  

8952 Schlieren, Grabenstrasse 11a

A team dedicated to develop innovative speciality medication for the treatment of severe wound-healing problems enabling significant improvements of patients quality of life. TOPADUR’s lead R&D programs are local active, highly potent, dual mode of action drugs. TOPADUR’s unique development candidates #3;work on validated drug targets resulting in higher than average clinical success chances.